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CirBACKGROUND Gadolinium-based contrast agents were not approved in the United States for detecting coronary
artery disease (CAD) prior to the current studies.
OBJECTIVES The purpose of this study was to determine the sensitivity and specificity of gadobutrol for detection of
CAD by assessing myocardial perfusion and late gadolinium enhancement (LGE) imaging.
METHODS Two international, single-vendor, phase 3 clinical trials of near identical design, “GadaCAD1” and “Gada-
CAD2,” were performed. Cardiovascular magnetic resonance (CMR) included gadobutrol-enhanced first-pass vasodilator
stress and rest perfusion followed by LGE imaging. CAD was defined by quantitative coronary angiography (QCA) but
computed tomography coronary angiography could exclude significant CAD.
RESULTS Because the design and results for GadaCAD1 (n ¼ 376) and GadaCAD2 (n ¼ 388) were very similar, results
were summarized as a fixed-effect meta-analysis (n ¼ 764). The prevalence of CAD was 27.8% defined by a $70% QCA
stenosis. For detection of a $70% QCA stenosis, the sensitivity of CMR was 78.9%, specificity was 86.8%, and area
under the curve was 0.871. The sensitivity and specificity for multivessel CAD was 87.4% and 73.0%. For detection of a
50% QCA stenosis, sensitivity was 64.6% and specificity was 86.6%. The optimal threshold for detecting CAD was
a $67% QCA stenosis in GadaCAD1 and $63% QCA stenosis in GadaCAD2.
CONCLUSIONS Vasodilator stress and rest myocardial perfusion CMR and LGE imaging had high diagnostic accuracy for
CAD in 2 phase 3 clinical trials. These findings supported the U.S. Food and Drug Administration approval of gadobutrol-
enhanced CMR (0.1 mmol/kg) to assess myocardial perfusion and LGE in adult patients with known or suspected CAD.
(J Am Coll Cardiol 2020;76:1536–47) Published by Elsevier on behalf of the American College of Cardiology Foundation.
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AND ACRONYM S
CI = confidence interval
FFR = invasive fractional flow
reserve
GBCA = gadolinium-based
contrast agents
LGE = late gadolinium
enhancement
QCA = quantitative coronary
angiography
SPECT = single-photon
emission computed
tomographyC MR is a reference standard for assessing ven-tricular function (1) and for imaging myocar-dial infarction (MI) (2). In meta-analysis,
stress perfusion CMR performs with high diagnostic
accuracy, particularly when compared with invasive
fractional flow reserve (FFR) (3). The MR INFORM
(MR Perfusion Imaging to Guide Management of Pa-
tients with Stable Coronary Artery Disease) clinical
trial (4) demonstrated that stress perfusion CMR can
safely manage patients with stable angina with less
revascularization but equivalent patient outcome to
an invasive FFR-guided strategy. Large prospective
single-center studies such as CE-MARC (Cardiovascu-
lar magnetic resonance and single-photon emission
computed tomography for diagnosis of coronary
heart disease) (5) and multicenter, multivendor
studies such as MR-IMPACT (Magnetic Resonance Im-
aging for Myocardial Perfusion Assessment in Coro-
nary artery disease Trial) (6) and MR-IMPACT II
(Magnetic Resonance Imaging for Myocardial Perfu-
sion Assessment in Coronary artery disease Trial II)
(7) showed that stress perfusion CMR has good diag-
nostic performance and is superior or not inferior to
single-photon emission computed tomography
(SPECT) (5,6,8). Stress perfusion CMR and LGE imag-
ing appear in multiple U.S. and international guide-
lines (9–11). Despite over 25 years of clinical trials
and validations, there was no U.S. Food and Drug
Administration (FDA) approval for gadolinium-based
contrast agents (GBCAs) for stress perfusion CMR or
LGE imaging in the United States prior to the current
2 clinical trials.SEE PAGE 1548GadaCAD1 and GadaCAD2 (Gadobutrol-enhanced
CMR to detect Coronary Artery Disease) were phase 3
clinical trials (NCT01890421 and NCT01890434)
designed to evaluate gadobutrol, a multipurpose
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United States, performed on Siemens CMR
scanners (Erlangen, Germany). Gadobutrol
(Gadavist Bayer Pharma AG, Leverkusen,
Germany) was previously FDA approved for
central nervous system magnetic resonance
imaging, for magnetic resonance angiography
in adult and pediatric patients including term
neonates, and for breast magnetic resonance
imaging in adult patients. Based on the
chemical structure of the gadolinium chelate,
gadobutrol is 1 of 3 macrocyclic GBCAs
currently on the market. It provides high
stability and high relaxivity (12,13).The specific aim of the GadaCAD clinical trials was
to assess the diagnostic accuracy of gadobutrol-
enhanced vasodilator stress perfusion CMR and LGE
imaging to detect CAD in 2 nearly identical studies
using an independent blinded read. The clinical trials
had requirements from the FDA to meet or exceed
specific diagnostic accuracy criteria for sensitivity
and specificity. Gadobutrol-enhanced perfusion CMR
had to have higher sensitivity than unenhanced stress
cine CMR wall motion for CAD detection. The stan-
dard of reference defining CAD was invasive coronary
angiography, but coronary computed tomography
angiography (CTA) could be used to exclude CAD.
METHODS
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CMR Image Acquisition
Invasive Coronary Angiography
• Within 6 weeks of CMR
• Core Laboratory QCA
• Could include or exclude CAD
CT Coronary Angiography
• Within 6 weeks of CMR
• Core Laboratory Interpretation
• Could only exclude CAD
Standard of Reference
or
Blinded, Independent Readers
• GadaCAD1: 3 blinded readers
• GadaCAD2: 3 blinded readers
• Total: 6 blinded readers
Interpretation 1
• Stress and rest perfusion
• Late Gadolinium Enhancement
Interpretation 2
• Stress and rest cine CMR
CMR Core Laboratory
GadaCAD1 and GadaCAD2 had very similar designs, standards of reference, and core laboratories. There were 3 blinded cardiac magnetic
resonance (CMR) readers for each study, and thus a total of 6 readers. CAD ¼ coronary artery disease; GadaCAD ¼ Gadobutrol-enhanced CMR
to detect Coronary Artery Disease; LGE ¼ late gadolinium enhancement; QCA ¼ quantitative coronary angiography.
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1538instability during the study period, revascularization
between CMR and coronary angiography, prior coro-
nary artery bypass graft, acute coronary syndrome, or
decompensated heart failure <14 days prior to inclu-
sion, certain arrhythmias, uncontrolled hypertension,
baseline hypotension <90 mm Hg, and estimated
glomerular filtration rate <30 ml/min/m2. Full inclu-
sion and exclusion criteria are available in
Supplemental Table 1.
All subjects signed written informed consent. The
studieswere conducted according to the Declaration of
Helsinki, the principles of Good Clinical Practice, and
were approved by the Health Authorities and local
Ethics Committee of each participating institution.EFFICACY ENDPOINTS. There were 3 coprimary
endpoints regarding detection of CAD defined as
a $50% and $70% QCA stenoses in 2 separate ana-
lyses: 1) the sensitivity for 2 of 3 readers had to be
high enough that the lower bound of the 95% confi-
dence interval (CI) was >60%; 2) the specificity for 2
of 3 readers had to be high enough that the lower
bound of the 2-sided 95% CI was >55%; and
3) gadobutrol-enhanced stress/rest perfusion and LGE
CMR had to have higher sensitivity than unenhanced
wall motion CMR images performed at stress and rest.
A CMR study was categorized as abnormal if either
stress perfusion or LGE was abnormal with 1 excep-
tion. If stress and rest perfusion were abnormal but
TABLE 1 Typical CMR Image Acquisition Parameters
Stress and
Rest Perfusion
Stress and
Rest Perfusion
Late Gadolinium Enhancement
Overview, Single Shot
Late Gadolinium Enhancement
High Resolution
Field strength 1.5-T 3-T 1.5- and 3-T 1.5- and 3-T
Sequence Saturation recovery, SSFP Saturation recovery, FLASH Inversion recovery* Inversion recovery*
Parallel imaging ePAT 2, GRAPPA with external
reference lines
ePAT 2, GRAPPA with external
reference lines
iPAT 2, GRAPPA, internal
reference lines
iPAT 2, GRAPPA, internal
reference lines
Slice orientation Short axis  3 slices Short axis  3 slices Short and long axis views Short axis views (with possible
additional views)
Spatial resolution 2.4  2.9  8.0 mm 1.9  2.5  8.0 mm 2.1  2.1  8.0 mm 1.3  1.3  8.0 mm
Temporal resolution, ms w110 ms w110 ms w200 ms w160 ms
Echo time, ms w1.0 ms w1.0 ms w1.0 ms w2.0 ms
Repetition time, ms w2.7 ms w2.9 ms w2.8 ms w5.9 ms
Inversion time, ms 100 ms 100 ms w300–380 ms w300–380 ms, optimized per patient
Trigger pulse Every heartbeat Every heartbeat Every other heartbeat Every other heartbeat
Typical acquisition parameters are listed; increases in field of view for larger patients will affect values for individual patients. Repetition time was estimated from temporal resolution and number of lines of
k-space acquired. Inversion time ranges were modified during GadaCAD1 and thus have a broad range, but were generally longer at 3-T than for 1.5-T. *Magnitude and phase sensitive reconstruction (PSIR).
ePAT¼ parallel image acceleration factor; FLASH¼ fast low angle shot; GRAPPA¼ Generalized Autocalibrating Partially Parallel Acquisitions; iPAT¼ parallel image acceleration factor; SSFP¼ steady state
free precession.
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1539LGE was normal, the perfusion finding was catego-
rized as an artifact and the study as normal.
Imag ing and vasod i la tor s t ress methods . The
study-specific procedures are summarized in Figure 1
and Table 1. The study used Siemens 1.5- and 3.0-T
CMR scanners running the “Cardiac Dot software”
that assists with image acquisition. Imaging included
segmented cine CMR, real-time cine CMR at baseline
and during stress, vasodilator stress and rest first-
pass perfusion CMR, and single-shot LGE imaging
about 5 min after rest perfusion, followed by
segmented LGE imaging (Table 1). Magnitude (14) and
phase-sensitive inversion recovery LGE images were
reconstructed (15). The inversion time suggested by
protocol could be adjusted by the technologist.
Gadobutrol 0.05 mmol/kg was injected at 4 ml/s
during vasodilator stress and again about 10 min later
for rest perfusion (total dose of 0.1 mmol/kg body
weight). No additional contrast was given for LGE
imaging. The vasodilator could be either adenosine
(140 mg/kg/min infusion for up to 6 min) or regade-
noson (0.4 mg intravenous injection) based on site
specific availability or preference. The rationale for
some of the CMR methods are detailed in the
Supplemental Appendix.
Core laboratory ana lyses . CMR studies were read
centrally, independently, and blinded to all non-
imaging data by a total of 6 experts with $5 years of
experience; 3 readers were assigned to each trial.
Image analysis was through a study-specific image
review program linked to the core laboratory image
archive. Stress perfusion, rest perfusion, and LGE
were summarized using the 17-segment American
Heart Association model, but omitted the apical
segment. Segments were read as normal, reversibleperfusion defect (stress only), fixed perfusion (stress
and rest), or mixed perfusion (reversible and fixed
components). For each reader, a study was abnormal
if $1 segment was not normal. Cine wall motion was
interpreted on a different day.
QCA was performed at a central core laboratory by
the consensus of 2 experts who were blinded to all
other data. Coronary artery stenoses were measured
in the left main, left anterior descending (LAD),
circumflex, and right coronary arteries if $2 mm in
diameter and were compared with corresponding
proximal reference segments (Medis, Leiden, the
Netherlands). The standard of reference was set
at $70% and at $50% diameter QCA stenosis. A
blinded, core laboratory assessment of coronary CTA
could exclude CAD in the absence of significant cor-
onary calcium and stenosis.
STATISTICAL ANALYSIS. Generally, 2 adequate and
well controlled trials are required to support FDA
approval of medications. The sample size for stress
perfusion CMR was determined by an assumed
sensitivity of 75% with a lower bound of the 95% CI of
60% and an assumed specificity of 67% with a lower
bound of the 95% CI of 55% and a 2-sided a-level of
0.05 and 90% power. These assumptions required a
sample size that included 110 subjects with CAD and
180 subjects without CAD. Because the prevalence of
disease could not be guaranteed, simulations were
considered over a range of prevalence from 30% to
60% leading to estimates of 375 subjects per trial for
approximately 80% power and assumed a disease
prevalence of 40% to 55%.
Efficacy analysis used data from all subjects who
underwent pharmacological stress, had complete
electronic clinical report forms, had adequate
TABLE 2 Demographics, Type of Stress, and Adverse Events
Subcategory GadaCAD1 GadaCAD2
Sample size 376 388
Age, yrs 58.5  12.0 58.9  10.2
Male 260 (69.1) 239 (61.4)
Ethnicity Hispanic 5 (1.3) 22 (5.7)
Non-Hispanic 365 (97.1) 366 (94.1)
Other 6 (1.6) 1 (0.3)
Race White 277 (73.7) 261 (67.1)
Black 2 (0.5) 67 (17.2)
Asian 94 (25.0) 48 (12.3)
Other 3 (0.8) 0 (0.0)
Country/region Europe 256 (68.1) None
United States 28 (7.4) 291 (75.0)
Korea 91 (24.2) None
Singapore None 22 (5.7)
Canada None 18 (4.6)
Australia/New Zealand 1 (0.3) 57 (14.7)
Risk factors Body mass index, kg/m2 27.1  4.6 29.3  5.3
Hypertension 228 (62.0) 251 (65.2)
Diabetes 89 (24.2) 108 (28.1)
Dyslipidemia 230 (62.5) 271 (70.4)
Family history CAD 143 (38.9) 151 (39.2)
Smoking 90 (24.5) 53 (13.8)
eGFR, ml/min/1.73 m2 84.2  18.4 82.0  18.7
Prior CAD MI 47 (12.8) 63 (16.4)
PCI 10 (2.7) 24 (6.2)
PCI with stent 59 (16.0) 74 (19.2)
CABG 0 (0.0) 0 (0.0)
Type of stress CMR 1.5-T 183 (48.7) 275 (70.9)
3.0-T 193 (51.3) 113 (29.1)
Adenosine 315 (83.8) 201 (51.8)
Regadenoson 61 (16.2) 187 (48.2)
Adverse events prior to gadobutrol Any AE 76 (17.8) 142 (29.7)
Stressor-related AE 64 (15.0) 136 (28.5)
Adverse events
<6 h after gadobutrol
Any AE 48 (11.3) 82 (17.2)
Stressor-related AE 20 (4.7) 49 (10.3)
Gadobutrol-related AE 3 (0.7) 1 (0.2)
Values are n, mean  SD, or n (%). Serious adverse events (AE) related to gadobutrol: death (0), anaphylaxis (1).
CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; CMR ¼ cardiac magnetic resonance;
eGFR ¼ estimated glomerular filtration rate; GadaCAD ¼ Gadobutrol-enhanced CMR to detect Coronary Artery
Disease; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention.
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determined by the core laboratory, and had complete
standard of reference images. The analysis was per-
formed on a per-subject basis.
Subject characteristics are presented as mean  SD
if normally distributed, and median (25%, 75% CI) if
not normally distributed. Diagnostic accuracy is
summarized by sensitivity, specificity, area under the
curve, positive predictive value, and negative pre-
dictive value. The 95% Clopper-Pearson CI were
calculated. Receiver-operator characteristic (ROC)
curves were determined from exact results at
thresholds ranging from a 20% QCA stenosis to a 95%QCA stenosis. ROC curves were compared with the
DeLong method (Supplemental Appendix).
Results were summarized at the individual reader
level, the clinical trial level, and as a meta-analysis
combining both clinical trials. To provide an overall
summary result, a fixed-effect meta-analysis
method was used to summarize diagnostic accuracy
statistics for the 6 readers. This methodology was
chosen as the 2 clinical trials had similar sensitivity
and specificity, nearly identical methodology, the
same study drug and dose, the same standard of
reference methods and core laboratories, and pop-
ulations with similar prevalence of CAD. At the
clinical trial level, the majority read was used to
determine whether the study was abnormal or
normal on a patient-by-patient basis. Majority read
meant the result by either 2 or 3 readers who came
to the same determination of a study being normal
or abnormal.
RESULTS
DEMOGRAPHICS. The GadaCAD studies were multi-
center, multinational studies enrolling patients with
an overall sample size for efficacy of 376 subjects in
GadaCAD1 and 388 subjects in GadaCAD2. For Gada-
CAD1 and GadaCAD2, safety was assessed in the 426
and 478 subjects who received gadobutrol. Inade-
quate CMR image quality led to exclusion of 17
(4.0%) and 26 (5.4%) subjects in GadaCAD1 and
GadaCAD2, respectively, while suitability of coronary
angiography or CTA led to exclusion of 28 (6.6%)
and 45 (9.4%) subjects, respectively (Supplemental
Table 2). The demographic characteristics of the
study participants are summarized in Table 2.
PREVALENCE OF CAD. In GadaCAD1, 12.8% of sub-
jects had a history of MI compared with 16.4% in
GadaCAD2 (Table 2). Fewer patients in GadaCAD1 had
a history of prior percutaneous coronary intervention
(PCI) (18.7%) than in GadaCAD2 (25.4%).
The post-testing prevalence of CAD was 28.7% in
GadaCAD1 and 27.1% in GadaCAD2 (Table 3) as defined
by the presence of at least 1 coronary artery
stenosis $70% by core laboratory QCA. In GadaCAD1,
the standard of reference was invasive angiography in
79.0% (297 of 376 subjects) and in GadaCAD2 was
68.0% (264 of 388 subjects) and coronary CTA in
remaining subjects.
Of the 108 subjects in GadaCAD1 with a $70% QCA
stenosis, 68 had single-vessel CAD and 40 had mul-
tivessel CAD defined as $70% QCA stenosis in 2 or
more coronary arteries. Of the 105 subjects in Gada-
CAD2 with a $70% QCA stenosis, 58 had single-vessel
TABLE 3 Prevalence of Coronary Artery Disease in GadaCAD1 and GadaCAD2
Coronary Artery Disease GadaCAD1 GadaCAD2
Sample size 376 388
Standard of reference $70% QCA
No significant CAD 268 (71.3) 283 (72.9)
$70% stenosis by QCA 108 (28.7) 105 (27.1)
Single-vessel CAD 68 (18.1) 58 (14.9)
Multivessel CAD 40 (10.6) 47 (12.1)
Standard of reference $50% QCA
No significant CAD 235 (62.5) 238 (61.3)
$50% stenosis by QCA 141 (37.5) 150 (39.9)
Single-vessel CAD 57 (15.1) 59 (15.2)
Multivessel CAD 84 (22.3) 91 (23.5)
QCA stenosis $50% but <70%* 33/141 (23.4) 45/150 (30.0)
Values are n, n (%), or n/N (%). *Total number is the number of subjects with $50% QCA stenosis.
CAD ¼ coronary artery disease; GadaCAD ¼ Gadobutrol-enhanced CMR to detect Coronary Artery Disease;
QCA ¼ quantitative coronary angiography.
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1541CAD and 47 had multivessel CAD. The proportions of
subjects with significant CAD, without significant
CAD, with single-vessel CAD, and with multivessel
disease were similar for the 2 trials.
For participants with a $50 QCA stenosis (Table 3),
many patients had intermediate-severity stenoses in
the range between 50% to <70% QCA stenosis. In
GadaCAD1, 33 of 141 subjects (23.4%) had
intermediate-severity stenoses and in GadaCAD2 the
proportion was 45 of 150 subjects (30.0%).
EXAMPLE OF IMAGE QUALITY. Figure 2 depicts im-
age quality from a participant who had no history of
MI but was found to have 2 small subendocardial in-
farctions by LGE imaging and vasodilator-inducible
perfusion defects that were more extensive than the
MIs (Videos 1, 2, 3, 4, 5, and 6).
DIAGNOSTIC ACCURACY VERSUS QCA STENOSIS.
The meta-analysis (Table 4, Figure 3) of both clinical
trials and all 6 readers provides a vantage point from
which to compare other levels of analysis, including
at the trial level and at the individual-reader level.
Against a standard of reference of a $70% QCA ste-
nosis, the sensitivity was 78.9% with a lower limit of
the 95% CI at 75.5% in the meta-analysis combining
both clinical trials. The specificity was 86.8% with a
lower limit of the 95% CI at 85.0%. The area under the
curve was 0.871 and corresponded to positive pre-
dictive value and negative predictive value of 69.7%
and 91.4%, respectively. The sensitivity for multi-
vessel CAD was 87.4% (95% CI: 77.0% to 97.2%) and
for single-vessel CAD was 73.05 (95% CI: 62.1%
to 84.0%).
Overall, the combined results represented the
sensitivity and specificity of the individual readers
quite well (Figure 3). In general, the sensitivity for
detecting a $70% QCA stenosis was slightly higher in
GadaCAD1 (81.5%) than GadaCAD2 (77.1%) as sum-
marized by the majority read (Table 4). Individually, 5
of the 6 readers were within 2.9% of the meta-
analysis sensitivity and were within 4.8% of the
meta-analysis specificity. In pairwise comparisons of
ROC curves, there were no significant differences
between readers within either clinical trial. The
Central Illustration summarizes the main study
methods and main study results.
For detection of a $50% QCA stenosis, the sensi-
tivity of the meta-analysis decreased to 64.6%, while
specificity was minimally different from the results
using a $70% QCA stenosis (Tables 4 and 5). For
GadaCAD1 and GadaCAD2 analyzed as individual tri-
als, sensitivity was within 2.1% and specificity was
within 1.1% of the combined results. At the reader
level, 5 of 6 readers had a sensitivity within 3.3% ofthe meta-analysis and all 6 readers had a specificity
within 3.5% of the meta-analysis.
SENSITIVITY ANALYSIS FOR INTERMEDIATE
STENOSIS (50% TO <70% BY QCA). By ROC analysis,
the optimal threshold for detecting CAD was a $67%
QCA stenosis in GadaCAD1 and a$63% QCA stenosis in
GadaCAD2 (Supplemental Table 3). To further analyze
the decrease in sensitivity between a $70% QCA ste-
nosis and a $50% QCA stenosis, 78 subjects had an
intermediate-severity stenosis defined as $50%
to <70% QCA stenosis (Table 3). In GadaCAD1, 18% of
subjects with an intermediate stenosis had an
abnormal CMR, whereas in GadaCAD2, 29% of subjects
with an intermediate stenosis had an abnormal CMR.
SUMMARY OF STUDY ENDPOINTS. The meta-
analysis combining results from the 6 readers
met all study endpoints for both definitions of
CAD: $70% QCA stenosis and $50% QCA stenosis
(Table 4). The lower bound of the 95% CI exceeded
the pre-defined thresholds for both sensitivity and
specificity. In addition, the sensitivity of gadobutrol-
enhanced perfusion and LGE CMR was better than
vasodilator-induced wall motion abnormalities
(Supplemental Table 4). With significant CAD
defined by a 70% QCA stenosis, all 6 readers met
every endpoint for sensitivity, specificity, and
the comparison with stress cine wall motion
(Supplemental Table 4). When defining CAD at a 50%
QCA stenosis, 5 of 6 readers did not meet or exceed
the lower limit of the sensitivity endpoint but all
readers met all other study endpoints (Table 5).
ADVERSE EVENTS. The great majority of adverse
events were stressor-related (Table 2). There were no
deaths. Of the 4 adverse events related to gadobutrol,
only 1 was considered serious: an anaphy-
lactic reaction.
FIGURE 2 Example of Image Quality
This patient had multivessel coronary stenoses and no clinically recognized prior myocardial infarction (MI), a 95% right coronary artery stenosis, 70% diagonal stenosis,
and a 50% obtuse marginal stenosis. Nonmotion-corrected stress perfusion images (bottom) show an obvious inferior and inferolateral perfusion defect (green arrows)
and a second less severe anterolateral perfusion defect (red arrows). The perfusion defects were more extensive than the small subendocardial MI detected with LGE
imaging (middle). See Videos 1, 2, 3, 4, 5, and 6, including the cine CMR (top), which showed a subtle inferior wall motion abnormality and perfusion images.
Abbreviations as in Figure 1.
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TABLE 4 Diagnostic Accuracy Statistics at the Individual Reader Level, Clinical Trial Level, and Level of Combined Results for Both Studies Versus the Standard of
Reference of a $70% Stenosis by QCA
Study Data Level
Sample
Size CAD(þ) CAD()
Sensitivity, %
(95% CI)
Specificity, %
(95% CI) AUC PPV, % NPV, % TP TN FP FN
GadaCAD1 and 2 Meta-analysis
6 readers
764 213 551 78.9 (75.5–82.0) 86.8 (85.0–88.3) 0.871 69.7 91.4 168 478 73 45
GadaCAD1 Clinical trial 376 108 268 81.5 (72.9–88.3) 89.6 (85.3–92.9) 0.880 75.9 92.3 88 240 28 20
GadaCAD2 Clinical trial 388 105 283 77.1 (67.9–84.8) 86.6 (82.0–90.3) 0.861 68.1 91.0 81 245 38 24
GadaCAD1 Reader 1 376 108 268 89.8 (82.5–94.8) 82.8 (77.8–87.2) NA 67.8 95.3 97 222 46 11
Reader 2 376 108 268 79.6 (70.8–86.8) 91.0 (87.0–94.2) NA 78.2 91.7 86 244 24 22
Reader 3 376 108 268 78.7 (69.8–86.0) 90.7 (86.5–93.9) NA 77.3 91.4 85 243 25 23
GadaCAD2 Reader 4 388 105 283 77.1 (67.9–84.8) 82.0 (77.0–86.3) NA 61.4 90.6 81 232 51 24
Reader 5 388 105 283 71.4 (61.8–79.8) 87.3 (82.8–90.9) NA 67.6 89.1 75 247 36 30
Reader 6 388 105 283 76.2 (66.9–84.0) 86.9 (82.4–90.6) NA 68.4 90.8 80 246 37 25
AUC ¼ area under the curve; CI ¼ confidence interval; FN ¼ false negative; FP ¼ false positive; NPV ¼ negative predictive value; PPV ¼ positive predictive value; TN ¼ true negative; TP ¼ true positive; other
abbreviations as in Table 3.
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The GadaCAD1 and GadaCAD2 studies were pivotal,
phase 3 clinical trials that led to FDA approval of
gadobutrol-enhanced CMR to assess stress and restFIGURE 3 Receiver-Operator Characteristic Curve for the Meta-Ana
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Rest Perfusion (normal)
Single Shot LGE (no myocardial infarction)
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Rest Real-time Cine (normal regional wall motion)
Cine Long Axis (normal global and regional function)
CMR Image Acquisition Order
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Arai, A.E. et al. J Am Coll Cardiol. 2020;76(13):1536–47.
The main findings in this patient were diffuse and severe perfusion defects during stress that were not present during rest perfusion imaging and the absence of a
myocardial infarction. The stress perfusion defect appears as a dark band about 50% to 75% in transmural extent in all segments with a thin band of brighter gray near
the epicardium (red arrows). Rest perfusion appears normal as documented by uniformly gray enhancement (green arrows). Both sets of late gadolinium enhancement
(LGE) images showed no myocardial infarction as the myocardium appears relatively uniformly black myocardium (cyan and yellow arrows). Cine short axis cardiac
magnetic resonance (CMR) in multiple, contiguous short-axis imaging planes provided measurements of left ventricular volumes, ejection fraction, and mass. Lower-
resolution real-time cine CMR were obtained before and during vasodilator stress to assess for induced regional wall motion abnormalities (RWMA), which cannot be
assessed on static images but were not seen on review of the video versions. Long-axis cine CMR confirmed the global and regional left ventricular function.
QCA ¼ quantitative coronary angiography.
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CMR with gadobutrol (0.1 mmol/kg dose, divided into
2 separate and equal injections) is now indicated in
the United States to assess stress and rest myocardial
perfusion and myocardial infarction in adult patients
with known or suspected CAD.
The results of GadaCAD1 and GadaCAD2 are in
accord with meta-analyses of CMR stress perfusion
(3), are comparable to the large CE-MARC study (5),
and are a slightly better than the MR IMPACT clinical
trials (6,7). In the European Society of Cardiovascular
Radiology MRCT registry, stress perfusion represents
w25% of CMR scans performed and had few moderate
or severe adverse events (16). Stress perfusion CMR
risk stratifies patients with stable angina in the
multicenter SPINS (Stress CMR Perfusion Imaging in
the United States) study (17), a negative CMR has lowlong-term cardiac events (18), and stress perfusion
CMR has low spending on subsequent ischemia
testing (19), a finding also applicable to European
economics (20).
A prior clinical trial aimed at getting approval for a
different GBCA to image MI (21) did not make it
through U.S. regulatory processes. Although the MR
IMPACT I and II clinical trials (6,7) brought approval
in several European countries, these studies did not
succeed in the FDA regulatory process, which
appeared to have focused on a 50% QCA stenosis, a
factor that may have contributed to low apparent
sensitivity as explained in subsequent paragraphs. As
a multivendor study, MR IMPACT II had a more
complicated trial design compared with the single-
vendor GadaCAD studies, but had superior diag-
nostic accuracy compared with SPECT (8).
TABLE 5 Diagnostic Accuracy Statistics at the Individual Reader Level, Clinical Trial Level, and Level of Combined Results for Both Studies Versus a Standard of
Reference of a $50% Stenosis by QCA
Study Data Level Sample Size CAD(þ) CAD() Sensitivity, % (95% CI) Specificity, % (95% CI) AUC PPV, % NPV, % TP TN FP FN
GadaCAD1 and 2 Meta-analysis
6 readers
764 291 473 64.6 (61.3–67.8) 88.6 (87.0–90.4) 0.871 78.0 80.3 188 420 159 103
GadaCAD1 Clinical trial 376 141 235 66.7 (58.2–74.4) 90.6 (86.2–94.0) 0.880 81.0 81.9 94 213 22 47
GadaCAD2 Clinical trial 388 150 238 62.7 (54.4–70.4) 89.5 (84.9–93.1) 0.861 79.0 79.2 94 213 25 56
GadaCAD1 Reader 1 376 141 235 76.6 (68.7–83.3) 85.1 (80.0–89.4) NA 75.5 85.8 108 200 35 33
Reader 2 376 141 235 65.2 (56.8–73.1) 92.3 (88.2–95.4) NA 83.6 81.6 92 217 18 49
Reader 3 376 141 235 64.5 (56.0–72.4) 91.9 (87.7–95.1) NA 92.7 81.2 91 216 19 50
GadaCAD2 Reader 4 388 150 238 64.7 (56.5–72.3) 85.3 (80.1–89.5) NA 73.5 79.3 97 203 35 53
Reader 5 388 150 238 56.0 (47.7–64.1) 88.7 (83.9–92.4) NA 75.7 76.2 84 211 27 66
Reader 6 388 150 238 61.3 (53.0–69.2) 89.5 (84.9–93.1) NA 78.6 78.6 92 213 25 58
Abbreviations as in Tables 3 and 4.
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has important clinical implications (17,22). Multiple
observational registries have demonstrated an asso-
ciation of revascularization with and survival benefit
in patients with extensive ischemia SPECT. Although
the randomized, controlled ISCHEMIA trial (23) did
not find a significant difference in hard outcomes in
patients with moderate or severe ischemia assigned
to an invasive strategy plus optimal medical therapy
(OMT) versus OMT alone, improved health status
outcomes in the invasive arm were observed
(17,22,24). Stress tests are recognized by all major
guidelines, and will continue to be used to diagnose
and manage CAD.
The published data on FFR suggest that managing
patients based on anatomic coronary artery stenoses
severity leads to higher rates of revascularization and
no benefit or worse outcomes compared with man-
aging patients based on physiological significance of
the stenosis by FFR (25–29). The MR INFORM study
(4) extended this concept to managing patients based
on stress perfusion CMR. MR INFORM was an un-
blinded, international, multicenter, prospective,
randomized, clinical-effectiveness trial. CMR was
noninferior to invasive FFR with respect to major
adverse cardiac events. Because the CMR strategy had
significantly fewer coronary revascularization pro-
cedures than invasive FFR, the CMR strategy has
potential to reduce costs.
The large number of intermediate-severity steno-
ses between 50% and <70% may have contributed to
the relatively low sensitivity for a $50% QCA stenosis
in the GadaCAD studies. It is widely accepted that
most 50% to <70% stenoses are not functionally sig-
nificant (30). In a post hoc analysis of the GadaCAD
data, the proportion of intermediate coronary steno-
ses that led to abnormal CMR scans was comparableto the fraction of intermediate-severity stenoses in
the FAME (Fractional Flow Reserve Versus Angiog-
raphy for Multivessel Evaluation) and DEFER
(Deferral of percutaneous coronary intervention)
studies that caused abnormal invasive FFR (30,31).
Although stress perfusion CMR has generally used
50% to 100% higher GBCA doses (32) than other in-
dications, the GadaCAD studies have proven that
single-dose gadobutrol (0.1 mmol/kg) is sufficient to
evaluate CAD (32). A dose ranging study concluded
that 0.1 mmol/kg of gadopentetate dimeglumine was
as efficacious as higher doses (33). For the GadaCAD
studies, the gadobutrol dose was based on the results
of a phase 2 clinical trial (Myocardial Perfusion MRI;
NCT01490294) that did not reveal benefit of
increasing the dose to 0.2 mmol/kg, but did show
benefit compared with a dose of 0.05 mmol/kg. The
published data does not support a dose-related ten-
dency for higher sensitivity for stress-perfusion CMR
at 0.2 mmol/kg (5,6,34–38) versus 0.15 mmol/kg
(7,39–41) and versus 0.1 mmol/kg (42–45) total doses
of GBCA. The Supplemental Materials describe
methods aimed at obtaining diagnostic quality im-
ages with the dose of contrast used.
The study did not recommend or exclude
aminophylline to reverse the vasodilators. Aminoph-
ylline is not generally needed for adenosine stress
due to the short half-life, but could be considered to
get closer to “rest” perfusion after regadenoson to
improve distinction of artifacts from perfusion de-
fects. LGE imaging is considered the most accurate
way to detect MI and improves interpretation of
stress perfusion CMR (46).
STUDY LIMITATIONS. A QCA reference to define CAD
is imperfect but practical for large-scale recruitment.
However, the 70% stenosis threshold is widely used
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: Stress perfusion CMR im-
aging with gadobutrol can be utilized to assess left
ventricular function, stress and rest perfusion, and the
transmural extent of MI in adults with known or sus-
pected CAD. Adverse and side effects of stress
perfusion CMR are dominated by those of the vaso-
dilator agent.
TRANSLATIONAL OUTLOOK: Additional prospec-
tive studies are needed to compare the sensitivity,
specificity, predictive value, advantages, and limita-
tions of gadobutrol-enhanced CMR for assessment of
CAD in specifically defined subpopulations.
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1546to infer the presence of hemodynamic significance of
the obstruction. Although FFR might have been a
more ideal reference standard, only about 3% of
subjects in the GadaCAD studies had FFR performed
clinically in a post-study survey (unpublished data, A.
Arai, March 2019). In the United States, invasive FFR
utilization remains relatively low despite clinical trial
evidence (27–29).
The GadaCAD trials did not test a higher dose of
gadobutrol or different specific GBCA so the results
should not be extrapolated beyond what was studied.
The GadaCAD trials were not designed to differentiate
diagnostic accuracy of different image acquisition
sequences or magnetic field strength. The studies
allowed use of adenosine or regadenoson as a vaso-
dilator due to divergent geographic preferences or
regulatory approval status. The study did not
randomize adenosine and regadenoson and, thus,
was not designed to compare these agents.
Despite methods aimed to obtain identical slices
for stress and rest perfusion, matching was not al-
ways perfect (Figure 2), but LGE images can also be
used to help interpret stress perfusion images (46).
CONCLUSIONS
Gadobutrol-enhanced CMR has high diagnostic accu-
racy for detecting CAD and is now FDA approved at adose of 0.1 mmol/kg to assess myocardial perfusion
and LGE in adults with known or suspected CAD.
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